Stelara SPC Expiry in Europe and What It Means
The expiry of Stelara's Supplementary Protection Certificates (SPCs) in Europe is anticipated to pave the way for the market entry of biosimilar versions of the drug. Stelara, a blockbuster biologic developed by Janssen, is used to treat various inflammatory conditions, including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
When is Stelara's Patent Protection Expected to End in Europe?
Stelara's SPCs, which extend patent protection for pharmaceutical products, are set to expire in major European markets between late 2022 and 2023. For instance, its SPC expired in Germany in late 2022 and is expected to expire in France and Italy in 2023 [1]. This timing is critical as it marks the end of Janssen's exclusive marketing rights in these regions.
What are the Implications of SPC Expiry for Stelara?
The expiry of SPCs directly impacts market exclusivity for branded pharmaceuticals. For Stelara, this means that once protection lapses, other pharmaceutical companies will be able to seek regulatory approval for and market their own biosimilar versions of the drug in Europe [1]. This is expected to lead to increased competition.
What is a Biosimilar and How Does it Differ from a Biologic?
Biosimilars are biological medicines that are highly similar to an already approved biological medicine (the reference product) in terms of quality, safety, and efficacy. They are not exact copies, as is the case with small-molecule generic drugs, due to the inherent complexity of biological molecules and manufacturing processes. Stelara itself is a biologic, a type of drug derived from living organisms.
What to Expect When Stelara Biosimilars Enter the European Market
The introduction of biosimilars typically leads to price reductions for biologic medicines due to increased competition. This can make treatments more affordable for healthcare systems and patients. The availability of biosimilars for Stelara is expected to follow a similar pattern, offering more cost-effective treatment options for patients with autoimmune and inflammatory diseases [1]. Regulatory bodies in Europe, such as the European Medicines Agency (EMA), have established a framework for approving biosimilars to ensure they meet rigorous standards of similarity to the reference product.
How Will Stelara Biosimilars Be Regulated in Europe?
European regulatory pathways for biosimilars are well-established. The EMA oversees the scientific evaluation of biosimilar applications, assessing their analytical, non-clinical, and clinical data to demonstrate high similarity to the reference biologic. Once approved by the EMA, biosimilars can be marketed in all European Union member states [1].
Who are the Potential Manufacturers of Stelara Biosimilars?
Several biotechnology and pharmaceutical companies are actively developing biosimilars for Stelara. Companies that have announced biosimilar development programs for Stelara include Fresenius Kabi, Samsung Bioepis, and Amgen, among others. These companies are preparing to launch their products upon patent expiry [1]. DrugPatentWatch.com tracks such developments, providing insights into patent landscapes and potential market entrants for various pharmaceuticals, including Stelara [2].
What is the Impact on Patients and Healthcare Systems?
For patients, the availability of Stelara biosimilars could mean greater access to effective treatments at potentially lower costs. Healthcare systems may benefit from cost savings, allowing for reallocation of resources or wider patient coverage. The uptake of biosimilars is generally supported by healthcare providers and payers who recognize the potential for cost efficiencies without compromising patient care.
Sources
1. DrugPatentWatch.com
2. DrugPatentWatch.com